An Optimized Surfactant-Based PEG-PLCL In Situ Gel Formulation For Enhanced Activity Of Rosuvastatin In Poloxamer-Induced Hyperlipidemic Rats

References

• Al-Tahami K, Singh J. Smart polymer based delivery systems for peptides and proteins. Recent Pat Drug Deliv Formul. 2007;1(1):65–71. doi:10.2174/18722110777981411319075875
   PubMedGoogle Scholar
• Huang X, Brazel CS. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release. 2001;73(2–3):121–136. doi:10.1016/S0168-3659(01)00248-611516493
   PubMed Web of Science ®Google Scholar
• Huang X, Brazel CS. Analysis of burst release of proxyphylline from poly(vinyl alcohol) hydrogels. Chem Eng Commun. 2003;190(4):519–532. doi:10.1080/00986440302081
   Web of Science ®Google Scholar
• Ahmed TA, Ibrahim HM, Samy AM, Kaseem A, Nutan MTH, Hussain MD. Biodegradable injectable in situ implants and microparticles for sustained release of montelukast: in vitro release, pharmacokinetics, and stability. AAPS PharmSciTech. 2014;15(3):772–780. doi:10.1208/s12249-014-0101-324648158
   PubMed Web of Science ®Google Scholar
• Mallapragada SK, Peppas NA, Colombo P. Crystal dissolution-controlled release systems. II. Metronidazole release from semicrystalline poly(vinyl alcohol) systems. J Biomed Mater Res. 1997;36(1):125–130. doi:10.1002/(ISSN)1097-4636.9212397
   PubMed Web of Science ®Google Scholar
• Pekarek KJ, Jacob JS, Mathiowitz E. Double-walled polymer microspheres for controlled drug release. Nature. 1994;367(6460):258–260. doi:10.1038/367258a08121490
   PubMed Web of Science ®Google Scholar
• Pandey SK, Haldar C, Patel DK, Maiti P. Biodegradable polymers for potential delivery systems for therapeutics. Adv Polym Sci. 2013;254:169–202. doi:10.1007/12_2012_198
   Web of Science ®Google Scholar
• Bhise K, Kotwal V, Saifee M, Inamdar N. Biodegradable polymers: which, when and why? Indian J Pharm Sci. 2007;69(5):616. doi:10.4103/0250-474X.38465
   Google Scholar
• Qi F, Wu J, Li H, Ma G. Recent research and development of PLGA/PLA microspheres/nanoparticles: a review in scientific and industrial aspects. Front Chem Sci Eng. 2018;1–14. doi:10.1007/s11705-018-1729-4
   Web of Science ®Google Scholar
• Daranarong D, Chan RTH, Wanandy NS, Molloy R, Punyodom W, Foster LJR. Electrospun polyhydroxybutyrate and poly(L-lactide-co-ε-caprolactone) composites as nanofibrous scaffolds. Biomed Res Int. 2014;2014:741408. doi:10.1155/2014/74140824900983
   PubMed Web of Science ®Google Scholar
• Jeong SI, Kim SH, Kim YH, et al. Manufacture of elastic biodegradable PLCL scaffolds for mechano-active vascular tissue engineering. J Biomater Sci Polym Ed. 2004;15(5):645–660. doi:10.1163/15685620432304690615264665
   PubMed Web of Science ®Google Scholar
• Jung Y, Kim SH, You HJ, Kim S-H, Ha Kim Y, Min BG. Application of an elastic biodegradable poly(L-lactide-co-ε-caprolactone) scaffold for cartilage tissue regeneration. J Biomater Sci Polym Ed. 2008;19(8):1073–1085. doi:10.1163/15685620878490933618644232
   PubMed Web of Science ®Google Scholar
• Díaz E, Sandonis I, Valle MB. In vitro degradation of poly(caprolactone)/nHA composites. J Nanomater. 2014;2014:1–8. doi:10.1155/2014/802435
   Web of Science ®Google Scholar
• Ibrahim HM, Ahmed TA, Hussain MD, et al. Development of meloxicam in situ implant formulation by quality by design principle. Drug Dev Ind Pharm. 2014;40:1. doi:10.3109/03639045.2012.74636023802149
   PubMed Web of Science ®Google Scholar
• Ahmed TA, Ibrahim HM, Ibrahim F, et al. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. J Pharm Sci. 2012;101(10):3753–3762. doi:10.1002/jps.2325022753324
   PubMed Web of Science ®Google Scholar
• Ahmed TA. Approaches to develop PLGA based in situ gelling system with low initial burst. Pak J Pharm Sci. 2015;28(2):657–665.25730797
   PubMed Web of Science ®Google Scholar
• Gurpreet S, Tanurajvir K, Ravinder Kaur AK. Recent biomedical applications and patents on biodegradable polymer-PLGA. Int J Pharmacol Pharm Sci. 2014;1(2):30–42.
   Google Scholar
• K KM, Mohanty D, Bakshil DV. An overview on design of experiment in product formulation. Res Rev J Pharm Nanotechnol. 2016:61–67.
   Google Scholar
• Asadi N, Zilouei H. Optimization of organosolv pretreatment of rice straw for enhanced biohydrogen production using Enterobacter aerogenes. Bioresour Technol. 2017;227:335–344. doi:10.1016/J.BIORTECH.2016.12.07328042989
   PubMed Web of Science ®Google Scholar
• Maged A, Haridy S, Shamsuzzaman M, Alsyouf I, Zaied R. Statistical monitoring and optimization of electrochemical machining using Shewhart Charts and response surface methodology. Int J Eng Mater Manuf. 2018;3(2):68–77. doi:10.26776/ijemm.03.02.2018.01
   Google Scholar
• Davies JT, Delfino SF, Feinberg CE, et al. Current and emerging uses of statins in clinical therapeutics: a review. Lipid Insights. 2016;9:13–29. doi:10.4137/LPI.S3745027867302
   PubMedGoogle Scholar
• Karasulu HY, Gundogdu E, Turk UO, et al. Enhancing solubility and bioavailability of rosuvastatin into self nanoemulsifying drug delivery system. Curr Drug Deliv. 2018;15(7):1072–1082. doi:10.2174/156720181566618022611454529484996
   PubMed Web of Science ®Google Scholar
• Li J, Yang M, Xu W. Development of novel rosuvastatin nanostructured lipid carriers for oral delivery in an animal model. Drug Des Devel Ther. 2018;12:2241–2248. doi:doi:10.2147/DDDT.S169522
   PubMed Web of Science ®Google Scholar
• Tarek A Ahmed, Yasser A Alharby, Abdel-Rahim M El-Helw, Khaled M Hosny, Khalid M El-Say. Depot injectable atorvastatin biodegradable in situ gel: development, optimization, in vitro, and in vivo evaluation. Drug Des Dev Ther 2016:10 405–415.
   Google Scholar
• Kurakula M, Ahmed TA. Co-delivery of atorvastatin nanocrystals in PLGA based in situ gel for anti-hyperlipidemic efficacy. Curr Drug Deliv. 2016;13:1–11. doi:10.2174/1567201813666151109102718
   Web of Science ®Google Scholar
• Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J Pharm Sci. 1969;58(10):1253–1257. doi:10.1002/jps.26005810215349114
   PubMed Web of Science ®Google Scholar
• Langenbucher F. Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol. 1972;24(12):979–981. doi:10.1111/j.2042-7158.1972.tb08930.x4146531
   PubMed Web of Science ®Google Scholar
• Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem. 1931;23(8):923–931. doi:10.1021/ie50260a018
   Google Scholar
• Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–1149. doi:10.1002/jps.260052121014088963
   PubMed Web of Science ®Google Scholar
• Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25–35. doi:10.1016/0378-5173(83)90064-9
   Web of Science ®Google Scholar
• Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv. 1985;60(4):110–111.4011621
   PubMedGoogle Scholar
• Baker RW, Lonsdale HS. Controlled release: mechanisms and release In: Taquary AC, Lacey RE, editors. Controlled Release of Biological Active Agents. New York: Plenum Press; 1974: 15–71. https://www.popline.org/node/495093: Accessed 427, 2019.
   Google Scholar
• Chaudhary HR, Brocks DR. The single dose poloxamer 407 model of hyperlipidemia; systemic effects on lipids assessed using pharmacokinetic methods, and its effects on adipokines. J Pharm Pharm Sci. 2013;16(1):65–73. doi:10.18433/J37G7M23683606
   PubMed Web of Science ®Google Scholar
• Reisin E, Liao J, Lee BS, et al. Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. Am J Med Sci. 2009;338(4):301–309. doi:10.1097/MAJ.0b013e3181b2719519826320
   PubMed Web of Science ®Google Scholar
• Georgieva-Kotetarova MT, Kostadinova II. Effect of atorvastatin and rosuvastatin on learning and memory in rats with diazepam-induced amnesia. Folia Med (Plovdiv). 2013;55(2):58–65. doi:10.2478/folmed-2013-001824191400
   PubMedGoogle Scholar
• Dalmoro A, Barba AA, Lamberti M, Mazzeo M, Venditto V, Lamberti G. Random l-lactide/ε-caprolactone copolymers as drug delivery materials. J Mater Sci. 2014;49(17):5986–5996. doi:10.1007/s10853-014-8317-x
   Web of Science ®Google Scholar
• Ibrahim HM, Ahmed TA, Hussain MD, et al. Development of meloxicam in situ implant formulation by quality by design principle. Drug Dev Ind Pharm. 2013;9045:1–8. doi:10.3109/03639045.2012.746360
   Web of Science ®Google Scholar
• Tefas LR, Tomuţă I, Achim M, Vlase L. Development and optimization of quercetin-loaded PLGA nanoparticles by experimental design. Clujul Med. 2015;88(2):214–223. doi:10.15386/cjmed-41826528074
   PubMedGoogle Scholar
• Xin C, Lihong W, Qiuyuan L, Hongzhuo L. Injectable long-term control-released in situ gels of hydrochloric thiothixene for the treatment of schizophrenia: preparation, in vitro and in vivo evaluation. Int J Pharm. 2014;469(1):23–30. doi:10.1016/j.ijpharm.2014.04.04424751344
   PubMed Web of Science ®Google Scholar
• DesNoyer JR, McHugh AJ. The effect of Pluronic on the protein release kinetics of an injectable drug delivery system. J Control Release. 2003;86(1):15–24. doi:10.1016/S0168-3659(02)00293-612490369
   PubMed Web of Science ®Google Scholar
• Patel RB, Carlson AN, Solorio L, Exner AA. Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. J Biomed Mater Res A. 2010;94(2):476–484. doi:doi:10.1002/jbm.a.3272420186771
   PubMed Web of Science ®Google Scholar
• Elias-Al-Mamun M, Khan HA, Dewan I, Jalil R-U. In vitro study on tamsulosin release kinetics from biodegradable PLGA in situ implants. Pak J Pharm Sci. 2009;22(4):360–367.19783512
   PubMed Web of Science ®Google Scholar
• Sousa Lobo JM, Costa P. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–133. doi:10.1016/S0928-0987(01)00095-111297896
   PubMed Web of Science ®Google Scholar
• Papadopoulou V, Kosmidis K, Vlachou M, Macheras P. On the use of the Weibull function for the discernment of drug release mechanisms. Int J Pharm. 2006;309(1–2):44–50. doi:10.1016/j.ijpharm.2005.10.04416376033
   PubMed Web of Science ®Google Scholar
• Kapure VJ, Pande VV, Deshmukh PK. Dissolution enhancement of rosuvastatin calcium by liquisolid compact technique. J Pharm. 2013;2013:315902. doi:10.1155/2013/315902
   Google Scholar
• Chavalitpanya K, Phattanarudee S. Poly(lactic acid)/polycaprolactone blends compatibilized with block copolymer. Energy Procedia. 2013;34:542–548. doi:10.1016/j.egypro.2013.06.783
   Google Scholar